CClinicalTrials.gg
RecruitingNCT04996342Updated Aug 9, 2021

A Cohort Study of Chronic Cardiovascular Diseases

An observational study in Cardiovascular Diseases and Cohort Studies, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-09.

Sponsored by Peking University First Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Study summary

This prospective cohort study aims to establish cohorts of patients with chronic cardiovascular disease, including refractory and secondary hypertension, coronary heart disease, atrial fibrillation, ventricular arrhythmias, structural heart disease, pulmonary hypertension, heart failure and rare diseases of the cardiovascular system, and patients with implantations of cardiac pacemaker, in order to dynamically describe the population characteristics, diagnosis and treatment status and long-term prognosis and analyze the factors affecting the choice of treatment plan, long-term management quality and clinical prognosis of these patients.

02

Conditions studied

  • Cardiovascular Diseases
  • Cohort Studies
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Peking University First Hospital is the lead sponsor of 378 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients hospitalized in the department of Cardiology or outpatient department of Peking University First Hospital will be enrolled if they are aged ≥18 years old, meet the inclusion criteria of each cohort for the 9 specific chronic cardiovascular disease, and need long-term follow-up according to the judgment of doctors after informed consent. Patients will be included in different disease-specific cohorts based on the disease status and treatment, including hypertension, coronary heart disease, arrhythmia (atrial fibrillation, ventricular arrhythmia), pacemaker surgery, structural heart disease, and heart failure, etc. The same patient who meets the inclusion criteria of multiple specific diseases can be entered into different cohorts at the same time. It is expected to enroll 1500 to 2000 patients per year.

Eligibility criteria

This study includes 9 disease-specific cohorts. The specific inclusion and exclusion criteria are as following:

  1. Refractory and secondary hypertension

    Inclusion Criteria:

    • Patients diagnosed as refractory hypertension and/or secondary hypertension
    • Patients willing to accept long-term follow-up and regular return visits

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
  2. Coronary heart disease

    Inclusion Criteria:

    • Patients undergoing coronary angiography and interventional therapy in the cath lab
    • Patients undergoing coronary angiography and functional assessment in the cath lab
    • Patients diagnosed as acute myocardial infarction

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
    • Regular return visits not available
  3. Atrial fibrillation

    Inclusion Criteria:

    • PAtrial fibrillation diagnosed by electrocardiogram or holter (duration >30 seconds)
    • Patients willing to accept long-term follow-up and regular return visits

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
    • New-onset atrial fibrillation during the perioperative period of major surgery
  4. Ventricular arrhythmias

    Inclusion Criteria:

    • Patients diagnosed as ventricular tachycardia, ventricular premature beat
    • Patients willing to accept long-term follow-up and regular return visits

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
    • A transient cause of ventricular arrhythmia was determined by the doctor, and long-term follow-up was not required
  5. Cardiac pacemaker implantation

    Inclusion Criteria:

    • Patients with permanent pacemaker implantations due to various causes (including bradycardia pacing, implantable cardioverter defibrillator, cardiac resynchronization therapy, leadless cardiac pacemaker, etc.)
    • Patients willing to accept long-term follow-up and regular return visits

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
  6. Structural heart disease

    Inclusion Criteria:

    • Patients diagnosed as structural heart disease, including congenital heart disease and severe valvular disease (moderate and above valvular stenosis or incomplete closure)
    • Patients willing to accept long-term follow-up and regular return visits

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
  7. Pulmonary hypertension

    Inclusion Criteria:

    • Patients diagnosed as pulmonary hypertension
    • Patients willing to accept long-term follow-up and regular return visits

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
  8. Heart failure

    Inclusion Criteria:

    • Patients diagnosed as heart failure
    • Patients willing to accept long-term follow-up and regular return visits

    Exclusion Criteria:

    • Severe diseases of other systems may affecting the life span of patients
  9. Rare diseases of the cardiovascular system

Inclusion Criteria:

  • Patients diagnosed as rare diseases in the catalog published by National Health Commission of the People's Republic of China
  • Patients willing to accept long-term follow-up and regular return visits

Exclusion Criteria:

  • Severe diseases of other systems may affecting the life span of patients
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events

    Time to the first occurence of Any cause death, myocardial infarction, or Stroke

    Time frame: 5 year

07

Study locations

1 of 1 sites recruiting
  • Division of Cardiology, Peking University First Hospital
    Beijing, 北京 100034, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04996342
Lead sponsor
Peking University First Hospital
Responsible party
Jianping LI (Director of Department of Cardiology, Peking University First Hospital) — Principal investigator
First posted
Aug 9, 2021
Start date
Apr 15, 2021
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 9, 2021

Study contacts

Jia Jia
Contact
jiajia9985@163.com
861083572283

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion